

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau(43) International Publication Date
19 June 2003 (19.06.2003)

PCT

(10) International Publication Number
WO 03/049667 A2

(51) International Patent Classification: A61K

(21) International Application Number: PCT/IB02/05516

(22) International Filing Date:
10 December 2002 (10.12.2002)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
1167/MUM/2001
10 December 2001 (10.12.2001) - IN

CZ, DB, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GH, GI,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LU, LV, MA, MD, MG, MK, MN, MW,
MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SK, SI,
TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States (regional): ARIPO patent (CH, GM,
KE, LS, MW, MZ, SD, SI, SZ, TZ, UG, ZM, ZW),
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
ML, MR, NI, SN, TD, TG).

Declaration under Rule 4.17:
of inventorship (Rule 4.17(iv)) for US only

(71) Applicant and:

(72) Inventor: KHAMAR, Bakulesh, Mansilal [IN/IN];
201, Ashadhin, Vasundhara Colony, Gulbati Tekra, 380006
Ahmedabad, Gujarat (IN).

Published:

without international search report and to be republished
upon receipt of that report

(81) Designated States (national): AR, AG, AI, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,

For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.

(54) Title: THE METHOD OF TREATING CANCER

(57) Abstract: Present invention relates to the method of treating cancer. According to present invention, a pharmaceutical com-
position made from "Mycobacterium w" (M_w) is found to be useful in the management of cancer. We have now found that the
same therapeutic agent is useful in management of cancer. The use of Mycobacterium w containing formulations is associated with
decrease in burden of cancer tissue, decreasing symptoms associated with cancer and improving quality of life. It also improves
tolerance to other therapies.

WO 03/049667 A2